IDEAYA Advances IDE892 into Monotherapy Expansion for MTAP-Deleted Cancers
Event summary
- IDEAYA Biosciences initiated Part 2 monotherapy expansion of IDE892 in Phase 1/2 trials for MTAP-deleted pancreatic and lung cancers.
- IDE892 achieved projected efficacious target exposures with no maximum tolerated dose reached yet.
- MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma (PDAC) and ~15% of non-small cell lung cancer (NSCLC).
- IDEAYA plans a Q4 2026 R&D Day to discuss combination strategies for targeting tumor heterogeneity in PDAC.
The big picture
IDEAYA Biosciences is positioning itself as a leader in precision oncology by targeting MTAP-deleted tumors, a subset with high unmet medical need. The company's focus on synthetic lethality and combination therapies aligns with broader industry trends toward more targeted cancer treatments. With no approved therapies for these specific genetic alterations, IDE892's progress could represent a significant breakthrough in treating pancreatic and lung cancers.
What we're watching
- Combination Strategy
- How IDEAYA's combination of IDE892 with IDE397 and Roche's pan-RAS inhibitor will impact treatment efficacy in MTAP-deleted cancers.
- Regulatory Milestones
- The pace at which IDEAYA advances its CDKN2A program toward an IND application in early 2027.
- Market Opportunity
- Whether IDE892 can capture significant market share given the lack of approved therapies for MTAP-deleted cancers.
Related topics